Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Istituto Oncologico Veneto IRCCS
M.D. Anderson Cancer Center
Providence Health & Services
M.D. Anderson Cancer Center
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
NRG Oncology
Washington University School of Medicine
University of Arizona
Grupo Espanol de Tumores Neuroendocrinos
University of Colorado, Denver
H. Lee Moffitt Cancer Center and Research Institute
University of Alabama at Birmingham
M.D. Anderson Cancer Center
City of Hope Medical Center
Baptist Health South Florida
Georgetown University
Emory University
Leiden University Medical Center
Emory University
Emory University
Hoosier Cancer Research Network
University of Pittsburgh
Dana-Farber Cancer Institute
Indiana University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Illinois at Chicago
Emory University
City of Hope Medical Center
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Fox Chase Cancer Center
Hospital of Macerata
Centre Leon Berard
M.D. Anderson Cancer Center
University of Kentucky
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
Washington University School of Medicine
Washington University School of Medicine
University of Utah
University of Texas Southwestern Medical Center
Institut Bergonié
Centre Francois Baclesse
Gustave Roussy, Cancer Campus, Grand Paris
M.D. Anderson Cancer Center